Share
UCART22 is intended for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. Credit: Animalculist/commons.wikimedia.org.

Cellectis has dosed the first patient in France in the BALLI-01 clinical study of UCART22 for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).

The company’s in-house manufactured product, UCART22 is an allogeneic CAR T-cell product candidate that targets CD22.

Related Company Profiles

View all

Designed to evaluate the safety and clinical activity, BALLI-01 is a Phase I/IIa open-label clinical study enrolling patients with r/r B-cell ALL after fludarabine, cyclophosphamide and alemtuzumab (FCA) lymphodepletion.

Cellectis chief medical officer Mark Frattini said: “Our team has worked tirelessly to expand our BALLI-01 clinical study (evaluating UCART22) to Europe.

“Dosing our first patient in France with our UCART22 product candidate manufactured in-house is an important advancement for Cellectis.

“By targeting the CD22 antigen, we aim at offering a novel therapeutic alternative to patients living with relapsed/refractory B-cell ALL, including those patients who have relapsed or did not respond to CD19-directed therapy.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Through its proprietary GMP manufacturing units, the company has started production of UCART in both Raleigh, North Carolina and Paris, France.

In addition, the company’s in-house manufacturing unit maximises the chances for eligible patients to be treated without delay.

The company said that its first France patient in the BALLI-01 trial was dosed with UCART22 in the 28-day dose limiting toxicity period. Using its gene editing technology, TALEN, and electroporation system, PulseAgile, Cellectis is developing new products to boost immunity and treat diseases with unmet medical needs.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.